Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
Hepp P, Fasching PA, Beckmann MW, Fehm T, Salmen J, Hagenbeck C, Jäger B, Widschwendter P, de Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Kurt AG, Friedl TWP, Janni W, Rack B. Hepp P, et al. Among authors: harbeck n. Clin Breast Cancer. 2018 Oct;18(5):e1103-e1110. doi: 10.1016/j.clbc.2018.06.006. Epub 2018 Jun 18. Clin Breast Cancer. 2018. PMID: 30017795
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kümmel S. Loibl S, et al. Among authors: harbeck n. Breast Cancer Res. 2008;10(5):R77. doi: 10.1186/bcr2144. Epub 2008 Sep 16. Breast Cancer Res. 2008. PMID: 18796139 Free PMC article.
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N. Schwarz-Dose J, et al. Among authors: harbeck n. J Clin Oncol. 2009 Feb 1;27(4):535-41. doi: 10.1200/JCO.2008.17.2650. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075273
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A. Lux MP, et al. Among authors: harbeck n. Onkologie. 2010;33(4):155-66. doi: 10.1159/000286233. Epub 2010 Mar 19. Onkologie. 2010. PMID: 20389141 Clinical Trial.
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P. von Minckwitz G, et al. Among authors: harbeck n. Breast Cancer Res Treat. 2011 Jan;125(1):145-56. doi: 10.1007/s10549-010-1228-x. Epub 2010 Nov 3. Breast Cancer Res Treat. 2011. PMID: 21042932 Free article.
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).
Beckmann MW, Blohmer JU, Costa SD, Diedrich K, Diel I, Eiermann W, Friese K, Gerber B, Harbeck N, Hilfrich J, Janni W, Jaenicke F, Jonat W, Kaufmann M, Kiechle M, Koehler U, Kreienberg R, von Minckwitz G, Moebus V, Nitz U, Schneeweiss A, Thomssen C, Wallwiener D. Beckmann MW, et al. Among authors: harbeck n. Breast Care (Basel). 2009;4(2):109-116. doi: 10.1159/000212164. Epub 2009 Apr 24. Breast Care (Basel). 2009. PMID: 21049070 Free PMC article.
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S. Untch M, et al. Among authors: harbeck n. J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788566 Clinical Trial.
689 results